1
Open
[.]
2
Close
[.]
3
Allotment
—
4
Listing
[.]
Issue Size
66,99,600 shares (agg. up to ₹[.] Cr)
Listing Date
[.]
✦ AI Insight
Restated Financials (₹ Cr.)
| Period Ended | 31 Dec 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 78.32 | 60.76 | 56.28 | 38.66 |
| Total Income | 95.67 | 81.86 | 47.12 | 29.18 |
| Profit After Tax | 8.51 | 4.67 | 0.72 | -0.20 |
| NET Worth | 20.14 | 11.63 | 6.96 | 6.24 |
| Reserves and Surplus | 16.25 | 7.74 | 3.07 | 2.35 |
| Total Borrowing | 20.82 | 19.97 | 15.79 | 15.02 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Bio Medica Laboratories Ltd. | SME | ₹52.43 Cr | ₹139 | 13.03 | ₹115.80 | -16.69% | ₹158.00 |
| Goldline Pharmaceutical Ltd. | SME | ₹11.61 Cr | ₹43 | 10.47 | ₹56.77 | +32.02% | ₹36.50 |
| Speciality Medicines Ltd. | SME | ₹29.14 Cr | ₹124 | 9.27 | ₹125.90 | +1.53% | ₹166.00 |
| Accretion Nutraveda Ltd. | SME | ₹24.77 Cr | ₹129 | 26.27 | ₹191.20 | +48.22% | ₹270.00 |
| KRM Ayurveda Ltd. | SME | ₹77.49 Cr | ₹135 | 17.32 | ₹180.70 | +33.85% | ₹307.70 |
| Curis Lifesciences Ltd. | SME | ₹27.52 Cr | ₹128 | 12.44 | ₹141.00 | +10.16% | ₹198.35 |
| Aptus Pharma Ltd. | SME | ₹13.02 Cr | ₹70 | 11.29 | ₹84.84 | +21.20% | ₹339.90 |
| Symbiotec Pharmalab Ltd. | Mainboard | ₹1,757.00 Cr | ₹988 | 55.44 | ₹1,097.70 | +11.10% | ₹1,133.45 |
| Hexagon Nutrition Ltd. | Mainboard | ₹138.87 Cr | ₹45 | 22.69 | ₹53.19 | +18.20% | ₹67.99 |
| Sai Parenteral's Ltd. | Mainboard | ₹408.79 Cr | ₹392 | 72.19 | ₹405.70 | +3.49% | ₹523.35 |
| Corona Remedies Ltd. | Mainboard | ₹655.37 Cr | ₹1062 | 43.47 | ₹1,438.40 | +35.44% | ₹2,236.10 |
| Rubicon Research Ltd. | Mainboard | ₹1,377.50 Cr | ₹485 | 55.75 | ₹628.20 | +29.53% | ₹1,835.40 |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Upgradation / Construction of the existing premises | 4.85 |
| 2 | Funding capital expenditure requirements for the purchase of plant & machinery and furniture & fixtures | 11.42 |
| 3 | Funding capital expenditure towards establishment of new office premise with interior works and utilities | |
| 4 | To meet working capital requirements of our Company | 19.50 |
| 5 | Repayment/prepayment, in part or full, of certain of our borrowings | |
| 6 | General Corporate Purposes |
About Maxwell Life Sciences IPO
Updated on Jun 25, 2025
Contact Details
Maxwell Life Sciences AddressOffice No. 5,Target Mall Chandrvarker Road,Borivali West, MumbaiMumbai, Maharashtra, 400092+91-022-45227279compliance@mlspl.inVisit Website